Eli Lilly reports Phase 3 trial win for oral GLP-1 in diabetes
Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary endpoint of lowering A1C by ...
